<DOC>
	<DOCNO>NCT00626613</DOCNO>
	<brief_summary>To evaluate relationship Risperidone Treatment , Treatment Discontinuation Rate , Quality Life patient Alzheimer 's Disease BPSD .</brief_summary>
	<brief_title>The Relationship Between Risperdal Treatment Quality Life Patients With Alzheimer 's Disease Behavioural Psychological Symptoms Dementia ( BPSD )</brief_title>
	<detailed_description>This interventional , placebo-controlled , double blind , prospective study . The total duration study 12 week . ( 1 ) . Baseline Phase : Subjects diagnose Alzheimer 's Disease BPSD evaluate entry trial . Subjects must meet inclusion/exclusion criterion enter treatment phase . After obtain informed consent , physical examination , brief neurologic examination , clinical laboratory test appropriate recommend . ( 2 ) . Treatment Phase : All patient enrol randomized treatment Risperdal Oral Solution Placebo . The dosage treatment medication begin 0.5 ml/ per day ( 0.5mg ) ( local product information leaflet ) . Investigators titrate dosage accord patient ' clinical situation . The maximum dose 2ml/ per day . The standardized assessment include NPI , cover 12 domain behavioral neuro-vegetative symptom , CASI cognitive function test , SF-36 Quality Life . Adverse event record .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Male female patient whose age 60 year old diagnose Alzheimer 's disease BPSD without exposure antipsychotic within 1 month prior study start . 2 . Subjects subject ' relative legal representative sign informed consent form , accordance regulation local ethical committee . 3 . Subjects must remain good health , determine medical history , complete physical examination , laboratory test ECG . 1 . Neurodegenerative disorder Parkinson 's disease , Pick 's disease Huntington 's chorea , Down 's syndrome , CreutzfeldtJacob disease . 2 . One follow condition possibly result cognitive impairment : Acute cerebral trauma cause post traumatic brain injury , subdural hematoma injury secondary chronic trauma ; hypoxic cerebral damage ; ; cerebral neoplasia ; ; mental retardation oligophrenia 3 . Multiinfarct dementia clinically active cerebrovascular disease 4 . Subjects severe coexist medical condition . 5 . Current clinically significant cardiovascular disease would expect limit subject 's ability participate complete 3month trial . 6 . History drug alcohol abuse within last year . 7 . Female subject childbearing potential without adequate contraception . 8 . History severe drug allergy hypersensitivity ; include record hypersensitivity Risperidone . 9 . Participation clinical trial investigational drug within 1 month ( 30 day ) prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>